The S&P/ASX 200 Index (ASX: XJO) is having another relatively poor session on Thursday. In afternoon trade, the benchmark index is down 0.2% to 8,164.1 points.
Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:
Image source: Getty Images
AGL Energy Limited (ASX: AGL)
The AGL Energy share price is down over 6% to $10.44. This appears to have been driven by a broker note out of Barrenjoey this morning. According to the AFR, the broker has cut its rating on the energy giant to underweight. That's the equivalent of a sell rating. It has also trimmed its earnings estimates and lowered its price target to $11.20 from $13.80.
Imugene Ltd (ASX: IMU)
The Imugene share price is down over 4% to 4.25 cents. This morning, the clinical stage immuno-oncology company released its quarterly update. Given that it is pre-revenue, Imugene was loss-making during the three months. The release reveals that it burned through a lot of cash during the quarter, which reduced its cash reserves from approximately $93 million to $54 million. It estimates that it has 2.3 more quarters of funding available.
Star Entertainment Group Ltd (ASX: SGR)
The Star Entertainment share price is down a further 7% to 23.7 cents. Investors have been selling the casino and resorts operator's shares following the release of its quarterly update this week. The struggling company posted an 18% decline in revenue to $351 million and an EBITDA loss of $18 million. Management said: "There continues to be a deterioration in operating performance from a challenging operating environment and the continued implementation of mandatory carded play and cash limits."
Woolworths Group Ltd (ASX: WOW)
The Woolworths share price is down a further 2% to $30.26. This supermarket giant's shares have been sold off since the release of its first quarter update on Wednesday. Woolworths reported a 4.5% increase in group sales over the prior corresponding period to $18 billion. However, management warned that Australian Food EBIT for the first half is forecast to be below its previous expectations. It now expects "H1 F25 EBIT, including $40 million of incremental supply chain costs, to be within a range of $1,480 million to $1,530 million compared to $1,595 million in H1 F24." The team at Goldman Sachs remains positive on the company. This morning, the broker retained its buy rating on its shares with a reduced price target of $36.20. This implies almost 20% upside for investors.
